B+
Bull case
0%
Probability
Target price
$58.00
-2.3% vs current
BTSG
BrightSpring Health ServicesBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$51.00
-14.1% vs current
B-
Bear case
0%
Probability
Target price
$42.00
-29.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+33.6
Score
AI commentary
Primary sources confirm a favorable May 1 earnings update with higher guidance, so headline tone is modestly positive. But this is still a T+3 follow-up with thin confirmed analyst-revision evidence, no usable social packet, and limited evidence on whether the initial reaction has held beyond the May 1 anchor close of $52.58. The memo should therefore remain tentative and monitoring-oriented rather than standard-conviction.
RankAlpha Sentiment Codex - 2026-05-04
Open full AI memoEvidence flagged
memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-05-01catalystQ1 beat-and-raise is the main near-term driverMedium impact
The earnings release furnished on May 1 showed Q1 continuing-operations revenue of $3.614B (+25.6% YoY), adjusted EBITDA of $190M (+44.8% YoY), and increased full-year 2026 revenue and adjusted EBITDA guidance, making post-print estimate digestion the key short catalyst. [#8-K-2026-05-01]
2026-12-31eventBalance-sheet simplification and remaining branch close-outs are a watch itemMedium impact
The Community Living divestiture closed on March 30, 2026, leverage was 2.27x at March 31, 2026, and management said the remaining three Amedisys/LHC branches are expected to close in 2026 subject to approvals; clean execution would support de-risking, while delays would cap upside. [#10-Q-2026-05-01]
2026-12-31catalystProvider and specialty pharmacy mix can keep growth above script volumeMedium impact
Q1 segment detail showed pharmacy revenue growth despite a 1.4% decline in prescriptions dispensed because revenue per script rose 27.0% and gross profit per script rose 49.5%, while provider revenue grew 27.9%; if this mix holds, BrightSpring can sustain better-than-volume earnings conversion through 2026. [#10-Q-2026-05-01]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology